Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Theranostics ; 13(1): 339-354, 2023.
Article in English | MEDLINE | ID: mdl-36593950

ABSTRACT

Rationale: Chemoresistance is a major challenge in the clinical management of patients with breast cancer. Mutant p53 proteins tend to form aggregates that promote tumorigenesis in cancers. We here aimed to explore the mechanism for the generation of mutant p53 aggregates in breast cancer and assess its role in inducing chemoresistance. Methods: Expression of BCL2-associated athanogene 2 (BAG2) was evaluated by qRT-PCR, western blotting, and immunohistochemistry in breast cancer patient specimens. The significance of BAG2 expression in prognosis was assessed by Kaplan-Meier survival analysis and the Cox regression model. The roles of BAG2 in facilitating the formation of mutant p53 aggregates were analyzed by co-immunoprecipitation, immunofluorescence, and semi-denaturing detergent-agarose gel electrophoresis assays. The effects of BAG2 on the chemoresistance of breast cancer were demonstrated by cell function assays and mice tumor models. Results: In the present study, we found that BAG2 was significantly upregulated in relapse breast cancer patient tissues and high BAG2 was associated with a worse prognosis. BAG2 localized in mutant p53 aggregates and interacted with misfolded p53 mutants. BAG2 exacerbated the formation of the aggregates and recruited HSP90 to promote the propagation and maintenance of the aggregates. Consequently, BAG2-mediated mutant p53 aggregation inhibited the mitochondrial apoptosis pathway, leading to chemoresistance in breast cancer. Importantly, silencing of BAG2 or pharmacological targeting of HSP90 substantially reduced the aggregates and increased the sensitivity of chemotherapy in breast cancer. Conclusion: These findings reveal a significant role of BAG2 in the chemoresistance of breast cancer via exacerbating mutant p53 aggregates and suggest that BAG2 may serve as a potential therapeutic target for breast cancer patients with drug resistance.


Subject(s)
Breast Neoplasms , Drug Resistance, Neoplasm , Molecular Chaperones , Tumor Suppressor Protein p53 , Animals , Mice , Cell Line, Tumor , Drug Resistance, Neoplasm/genetics , HSP90 Heat-Shock Proteins/metabolism , Neoplasm Recurrence, Local , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Molecular Chaperones/genetics , Molecular Chaperones/metabolism , Breast Neoplasms/genetics , Humans , Female
2.
Cell Rep ; 42(6): 112542, 2023 06 27.
Article in English | MEDLINE | ID: mdl-37210725

ABSTRACT

Alternative splicing (AS) is a critical mechanism for the aberrant biogenesis of long non-coding RNA (lncRNA). Although the role of Wnt signaling in AS has been implicated, it remains unclear how it mediates lncRNA splicing during cancer progression. Herein, we identify that Wnt3a induces a splicing switch of lncRNA-DGCR5 to generate a short variant (DGCR5-S) that correlates with poor prognosis in esophageal squamous cell carcinoma (ESCC). Upon Wnt3a stimulation, active nuclear ß-catenin acts as a co-factor of FUS to facilitate the spliceosome assembly and the generation of DGCR5-S. DGCR5-S inhibits TTP's anti-inflammatory activity by protecting it from PP2A-mediated dephosphorylation, thus fostering tumor-promoting inflammation. Importantly, synthetic splice-switching oligonucleotides (SSOs) disrupt the splicing switch of DGCR5 and potently suppress ESCC tumor growth. These findings uncover the mechanism for Wnt signaling in lncRNA splicing and suggest that the DGCR5 splicing switch may be a targetable vulnerability in ESCC.


Subject(s)
Esophageal Neoplasms , Esophageal Squamous Cell Carcinoma , RNA, Long Noncoding , Humans , Esophageal Squamous Cell Carcinoma/genetics , RNA, Long Noncoding/genetics , Esophageal Neoplasms/genetics , Inflammation/genetics , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Cell Proliferation/genetics , Cell Movement/genetics
3.
J Hematol Oncol ; 14(1): 6, 2021 01 06.
Article in English | MEDLINE | ID: mdl-33407765

ABSTRACT

BACKGROUND: HOMER family scaffolding proteins (HOMER1-3) play critical roles in the development and progression of human disease by regulating the assembly of signal transduction complexes in response to extrinsic stimuli. However, the role of HOMER protein in breast cancer remains unclear. METHODS: HOMER3 expression was examined by immunohistochemistry in breast cancer patient specimens, and its significance in prognosis was assessed by Kaplan-Meier survival analysis. The effects of HOMER3 in growth factor-induced ß-Catenin activation were analyzed by assays such as TOP/FOP flash reporter, tyrosine phosphorylation assay and reciprocal immunoprecipitation (IP) assay. Role of HOMER3 in breast cancer metastasis was determined by cell function assays and mice tumor models. RESULTS: Herein, we find that, among the three HOMER proteins, HOMER3 is selectively overexpressed in the most aggressive triple negative breast cancer (TNBC) subtype, and significantly correlates with earlier tumor metastasis and shorter patient survival. Mechanismly, HOMER3 interacts with both c-Src and ß-Catenin, thus providing a scaffolding platform to facilitate c-Src-induced ß-Catenin tyrosine phosphorylation under growth factor stimulation. HOMER3 promotes ß-Catenin nuclear translocation and activation, and this axis is clinically relevant. HOMER3 promotes and is essential for EGF-induced aggressiveness and metastasis of TNBC cells both in vitro and in vivo. CONCLUSION: These findings identify a novel role of HOMER3 in the transduction of growth factor-mediated ß-Catenin activation and suggest that HOMER3 might be a targetable vulnerability of TNBC.


Subject(s)
Homer Scaffolding Proteins/metabolism , Lung Neoplasms/secondary , Triple Negative Breast Neoplasms/pathology , beta Catenin/metabolism , Animals , Cell Line, Tumor , Female , Humans , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Mice, Inbred BALB C , Mice, Nude , Phosphorylation , Triple Negative Breast Neoplasms/metabolism , Tyrosine/metabolism
4.
Am J Physiol Endocrinol Metab ; 298(3): E565-76, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19996382

ABSTRACT

Tribbles homolog 3 (TRIB3) was found to inhibit insulin-stimulated Akt phosphorylation and modulate gluconeogenesis in rodent liver. Currently, we examined a role for TRIB3 in skeletal muscle insulin resistance. Ten insulin-sensitive, ten insulin-resistant, and ten untreated type 2 diabetic (T2DM) patients were metabolically characterized by hyperinsulinemic euglycemic glucose clamps, and biopsies of vastus lateralis were obtained. Skeletal muscle samples were also collected from rodent models including streptozotocin (STZ)-induced diabetic rats, db/db mice, and Zucker fatty rats. Finally, L6 muscle cells were used to examine regulation of TRIB3 by glucose, and stable cell lines hyperexpressing TRIB3 were generated to identify mechanisms underlying TRIB3-induced insulin resistance. We found that 1) skeletal muscle TRIB3 protein levels are significantly elevated in T2DM patients; 2) muscle TRIB3 protein content is inversely correlated with glucose disposal rates and positively correlated with fasting glucose; 3) skeletal muscle TRIB3 protein levels are increased in STZ-diabetic rats, db/db mice, and Zucker fatty rats; 4) stable TRIB3 hyperexpression in muscle cells blocks insulin-stimulated glucose transport and glucose transporter 4 (GLUT4) translocation and impairs phosphorylation of Akt, ERK, and insulin receptor substrate-1 in insulin signal transduction; and 5) TRIB3 mRNA and protein levels are increased by high glucose concentrations, as well as by glucose deprivation in muscle cells. These data identify TRIB3 induction as a novel molecular mechanism in human insulin resistance and diabetes. TRIB3 acts as a nutrient sensor and could mediate the component of insulin resistance attributable to hyperglycemia (i.e., glucose toxicity) in diabetes.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Glucose/metabolism , Insulin Resistance/genetics , Insulin/metabolism , Muscle, Skeletal/physiopathology , Protein Kinases/metabolism , Adult , Animals , Female , Humans , Male , Mice , Protein Serine-Threonine Kinases/antagonists & inhibitors , Rats , Rats, Zucker
5.
Endocrinology ; 143(12): 4897-906, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12446617

ABSTRACT

Androgens are critical for prostate development, growth, and functions. In general, they support proliferation and prevent cell death of prostatic epithelial cells. Here, we studied changes of gene expression after castration and testosterone replacement therapy in the rat ventral prostate using cDNA microarrays analysis. We could identify 230 genes that were regulated in either experimental condition. Using hierarchical clustering analysis, different groups of genes could be detected according to their expression pattern. This enabled us to distinguish the putative androgen-responsive genes from the secondary-responsive ones. Among genes that altered during castration and testosterone replacement, a set of oxidative stress-related genes, including thioredoxin, peroxiredoxin 5, superoxide dismutase 2, glutathione peroxidase 1, selenoprotein 15 kDa, microsomal glutathione-S-transferase, glutathione reductase, and epoxide hydrolase, were changed by castration. We hypothesize that modulation of redox status can be a factor of relevance in androgen withdrawal-induced prostate apoptosis. In selective cases, quantitative RT-PCR was used to confirm changes in gene expression. Immunohistochemistry was performed to detect thioredoxin and ezrin. Both of these were detected in the prostate and seem to be regulated in a similar manner as shown by gene expression analysis. In conclusion, gene expression profiling provides a unique opportunity for understanding the molecular mechanisms of androgen actions in prostate gland.


Subject(s)
Androgens/deficiency , Apoptosis , Gene Expression Profiling , Oxidative Stress/genetics , Prostate/cytology , Animals , Cytoskeletal Proteins , Epoxide Hydrolases/genetics , Glutathione Peroxidase/genetics , Glutathione Reductase/genetics , Glutathione Transferase/genetics , Hormone Replacement Therapy , Immunohistochemistry , Male , Orchiectomy , Oxidation-Reduction , Peroxidases/genetics , Peroxiredoxins , Phosphoproteins/analysis , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction , Superoxide Dismutase/genetics , Testosterone/administration & dosage , Thioredoxins/analysis , Thioredoxins/genetics
6.
Endocrinology ; 145(4): 1972-9, 2004 Apr.
Article in English | MEDLINE | ID: mdl-14684613

ABSTRACT

The aim of this study was to identify genes for hepatic fuel metabolism with a gender-differentiated expression and to determine which of these that might be regulated by the female-specific secretion of GH. Effects of gender and continuous infusion of GH to male rats were studied in the liver using cDNA microarrays representing 3200 genes. Sixty-nine transcripts displayed higher expression levels in females, and 177 displayed higher expression in males. The portion of GH-regulated genes was the same (30%) within the two groups of gender-specific genes. The male liver had a higher expression of genes involved in fuel metabolism, indicating that male rats might have a greater capacity for high metabolic turnover, compared with females. Most notable among the female-predominant transcripts was fatty acid translocase/CD36, with 18-fold higher mRNA levels in the female liver and 4-fold higher mRNA levels in males treated with GH, compared with untreated males. This gender-differentiated expression was confirmed at mRNA and protein levels in the rat and at the mRNA level in human livers. Although purely speculative, it is possible that higher levels of fatty acid translocase/CD36 in human female liver might contribute to the sexually dimorphic development of diseases resulting from or characterized by disturbances in lipid metabolism, such as arteriosclerosis, hyperlipidemia, and insulin resistance.


Subject(s)
CD36 Antigens/metabolism , Liver/metabolism , Organic Anion Transporters/metabolism , Sex Characteristics , Adult , Animals , CD36 Antigens/genetics , Female , Humans , Male , Middle Aged , Oligonucleotide Array Sequence Analysis , Organic Anion Transporters/genetics , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley
7.
J Steroid Biochem Mol Biol ; 80(1): 77-83, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11867266

ABSTRACT

To investigate the expression of Bcl-2, Bcl-x, Mcl-1, Bax and Bak proteins in human uterine leiomyomas and homologous myometrium during the menstrual cycle and after menopause. The expression of Bcl-2, Bcl-x, Mcl-1, Bax and Bak in leiomyomas (n=24) and myometrial samples (n=22) from women with leiomyomas was measured by immunohistochemistry and Western blot. Measured by immunohistochemistry, a significant difference between leiomyomas and myometrium was observed only for the Bax protein, in tissues obtained from women in the secretory phase of the menstrual cycle. The Bcl-2 staining was more abundant in leiomyomas than in myometrium only in tissues obtained in the proliferative phase of the cycle. Bcl-2 was more abundant in leiomyomas from women of fertile age than in leiomyomas from menopausal women. No significant differences were observed for the Bcl-x or Bak proteins, whereas the Mcl-1 protein was significantly less abundant in secretory phase leiomyomas than in leiomyomas from menopausal women. Western blot analysis based on pools of tissue extracts from the different groups essentially confirmed the data obtained by immunohistochemistry. Bcl-2 family proteins are expressed in leiomyomas and myometrium in different phases related to and influenced by gonadal steroids. These proteins are suggested to interact with each other in the regulation of programmed cell death, apoptosis, but their specific role in growth control of uterine leiomyomas remains to be investigated.


Subject(s)
Leiomyoma/metabolism , Membrane Proteins/metabolism , Myometrium/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Proto-Oncogene Proteins/metabolism , Uterine Neoplasms/physiopathology , Apoptosis/physiology , Female , Humans , Immunoblotting , Leiomyoma/pathology , Membrane Proteins/genetics , Menopause/metabolism , Menstrual Cycle/physiology , Myeloid Cell Leukemia Sequence 1 Protein , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins c-bcl-2/genetics , Uterine Neoplasms/pathology , bcl-2 Homologous Antagonist-Killer Protein , bcl-2-Associated X Protein , bcl-X Protein
8.
Fertil Steril ; 78(5): 985-93, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12413982

ABSTRACT

OBJECTIVE: To determine mRNA and protein expression of the progesterone receptor (PR) and insulin-like growth factor-I (IGF-I) in myometrium and fibroids. DESIGN: Retrospective clinical study. SETTING: Hospital-based and university-affiliated research laboratories. PATIENT(S): Twelve women in the proliferative phase and six women treated with GnRH analogue (GnRH-a). INTERVENTION(S): Blood sampling and collection of myometrium and fibroids. MAIN OUTCOME MEASURE(S): PR and IGF-I mRNA levels in fibroids and myometrium were analyzed by solution hybridization and in situ hybridization whereas the proteins were localized by immunohistochemistry. RESULT(S): Fibroids and myometrium from women in the proliferative phase showed significantly higher PR mRNA than the corresponding tissues from GnRH-a-treated women. The amount of cells positively stained for PR-AB and PR-B in fibroids and myometrium decreased after GnRH-a treatment compared with in the proliferative phase. The IGF-I mRNA in both fibroids and myometrium in the proliferative phase was significantly higher than those after GnRH-a treatment. The immunostaining of IGF-I showed no difference between the two tissues. There was weaker immunostaining in the GnRH-a-treated group compared with in the proliferative phase group. CONCLUSION(S): The shrinkage of fibroids after steroid deprivation is associated with alterations in PR and IGF-I expression.


Subject(s)
Gonadotropin-Releasing Hormone/analogs & derivatives , Insulin-Like Growth Factor I/metabolism , Leiomyoma/drug therapy , Leiomyoma/metabolism , Myometrium/metabolism , Receptors, Progesterone/metabolism , Adult , Antineoplastic Agents, Hormonal/therapeutic use , Female , Follicular Phase/physiology , Goserelin/therapeutic use , Humans , Immunohistochemistry , Insulin-Like Growth Factor I/genetics , Leiomyoma/physiopathology , Middle Aged , Myometrium/drug effects , RNA, Messenger/metabolism , Receptors, Progesterone/genetics
9.
J Appl Physiol (1985) ; 110(3): 746-55, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21109598

ABSTRACT

Genes influencing resting energy expenditure (REE) and respiratory quotient (RQ) represent candidate genes for obesity and the metabolic syndrome because of the involvement of these traits in energy balance and substrate oxidation. We aim to explore the molecular basis for individual variation in REE and fuel partitioning as reflected by RQ. We performed microarray studies in human vastus lateralis muscle biopsies from 40 healthy subjects with measured REE and RQ values. We identified 2,392 and 1,115 genes significantly correlated with REE and RQ, respectively. Genes correlated with REE and RQ encompass a broad array of functions, including carbohydrate and lipid metabolism, gene expression, mitochondrial processes, and membrane transport. Microarray pathway analysis revealed that REE was positively correlated with upregulation of G protein-coupled receptor signaling (meet criteria/total genes: 65 of 283) involved in autonomic nervous system functions, including those receptors mediating adrenergic, dopamine, γ-aminobutyric acid (GABA), neuropeptide Y (NPY), and serotonin action (meet criteria/total genes: 46 of 176). Reduced REE was associated with an increase in genes participating in ubiquitin-proteasome-dependent proteolytic pathways (58 of 232). Serine-type peptidase activity (9 of 76) was positively correlated with RQ, while genes involved in the protein phosphatase type 2A complex (4 of 9), mitochondrial function and cellular respiration (38 of 315), and unfolded protein binding (19 of 97) were associated with reduced RQ values and a preference for lipid fuel metabolism. Individual variations in whole body REE and RQ are regulated by differential expressions of specific genes and pathways intrinsic to skeletal muscle.


Subject(s)
Energy Metabolism/physiology , Muscle Proteins/metabolism , Muscle, Skeletal/physiology , Oxygen Consumption/physiology , Rest/physiology , Signal Transduction/physiology , Adult , Female , Gene Expression Regulation/physiology , Humans , Male
10.
Endocrine ; 31(1): 5-17, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17709892

ABSTRACT

To study the insulin effects on gene expression in skeletal muscle, muscle biopsies were obtained from 20 insulin sensitive individuals before and after euglycemic hyperinsulinemic clamps. Using microarray analysis, we identified 779 insulin-responsive genes. Particularly noteworthy were effects on 70 transcription factors, and an extensive influence on genes involved in both protein synthesis and degradation. The genetic program in skeletal muscle also included effects on signal transduction, vesicular traffic and cytoskeletal function, and fuel metabolic pathways. Unexpected observations were the pervasive effects of insulin on genes involved in interacting pathways for polyamine and S-adenoslymethionine metabolism and genes involved in muscle development. We further confirmed that four insulin-responsive genes, RRAD, IGFBP5, INSIG1, and NGFI-B (NR4A1), were significantly up-regulated by insulin in cultured L6 skeletal muscle cells. Interestingly, insulin caused an accumulation of NGFI-B (NR4A1) protein in the nucleus where it functions as a transcription factor, without translocation to the cytoplasm to promote apoptosis. The role of NGFI-B (NR4A1) as a new potential mediator of insulin action highlights the need for greater understanding of nuclear transcription factors in insulin action.


Subject(s)
Gene Expression Regulation/physiology , Hyperinsulinism/metabolism , Insulin/physiology , Muscle, Skeletal/metabolism , Adult , Cells, Cultured , DNA-Binding Proteins/metabolism , DNA-Binding Proteins/physiology , Female , Gene Expression Profiling , Glucose Clamp Technique , Humans , Male , Metabolic Networks and Pathways/genetics , Middle Aged , Nuclear Receptor Subfamily 4, Group A, Member 1 , Oligonucleotide Array Sequence Analysis , Receptors, Cytoplasmic and Nuclear/metabolism , Receptors, Cytoplasmic and Nuclear/physiology , Receptors, Steroid/metabolism , Receptors, Steroid/physiology , Reverse Transcriptase Polymerase Chain Reaction , Transcription Factors/genetics , Transcription Factors/metabolism , Transcription Factors/physiology
11.
Gynecol Obstet Invest ; 55(4): 225-30, 2003.
Article in English | MEDLINE | ID: mdl-12904697

ABSTRACT

The content of RNA and DNA in human myometrium and fibroids obtained at different endocrine conditions varied, with the highest RNA/DNA ratio in tissues from pregnant patients, intermediate ratios in women during the menstrual cycle and the lowest in tissues from postmenopausal and GnRHa-treated patients. mRNA expression of two house-keeping genes, gamma-actin and GAPDH, was highest in myometrium from pregnant women, intermediate in untreated women of fertile age and lowest in tissues from GnRHa-treated and postmenopausal women. To control for degradation of nucleic acids when measuring mRNA expression, we suggest additional analysis of gene(s), where the expression pattern is known, and that expression, whenever possible, is related to DNA, which is a more stable parameter than RNA and total nucleic acids, when there are differences in proliferation between tissues and/or groups of patients.


Subject(s)
DNA/genetics , Gene Expression , Leiomyoma/metabolism , Myometrium/metabolism , RNA, Messenger/genetics , Uterine Neoplasms/metabolism , Actins/genetics , Adult , Aged , Female , Glyceraldehyde-3-Phosphate Dehydrogenases/genetics , Goserelin/pharmacology , Humans , Leiomyoma/genetics , Menstrual Cycle , Middle Aged , Postmenopause , Pregnancy , Pregnancy Complications, Neoplastic/metabolism , Uterine Neoplasms/genetics
12.
Biol Reprod ; 69(4): 1308-17, 2003 Oct.
Article in English | MEDLINE | ID: mdl-12801995

ABSTRACT

The development and functions of female reproductive tissues are regulated by the actions of two major sex steroid hormones, estrogen and progesterone. To investigate estrogen-dependent gene expression in the rat uterus, we studied the effect of ovariectomy with or without estrogen treatment on the uterine expression of 3000 genes using cDNA microarrays. Many genes were regulated by either treatment, but only few were reciprocally regulated by these contrasting treatments. The present study confirms previous findings and identifies several genes with expressions not previously known to be influenced by estrogen. These genes include follistatin-related protein, Thy-1 glycoprotein, alpha-fodrin, CD24, immediate early response 5, insulin-like growth factor-binding protein 2, growth response protein CL-6 (INSIG-1), ladinin1, class I major histocompatibility complex heavy chain, lactadherin, ezrin, and Fas-activated serine/threonine kinase. Because of their function as regulators of proliferation and apoptosis, CD24, insulin-like growth factor-binding protein 2, and Fas/Fas ligand were examined further by immunohistochemical expression and tissue localization analysis. Our analysis confirms a contrasting regulation of these gene products by ovariectomy and estrogen treatment. The present study identifies novel mediators of estrogen actions in the uterus and provides genome-wide expression data from which novel hypotheses regarding uterine function can be generated.


Subject(s)
Estradiol/pharmacology , Gene Expression Profiling , Gene Expression Regulation/drug effects , Membrane Proteins , Ovariectomy/adverse effects , Uterus/physiology , Animals , Antigens, CD/genetics , Antigens, CD/metabolism , Apoptosis/drug effects , Apoptosis/genetics , CD24 Antigen , Carrier Proteins/genetics , Cytoskeletal Proteins , Fas Ligand Protein , Female , Follistatin-Related Proteins/genetics , Immunohistochemistry/methods , Insulin-Like Growth Factor Binding Protein 2/genetics , Insulin-Like Growth Factor Binding Protein 2/metabolism , Intracellular Signaling Peptides and Proteins , Membrane Glycoproteins/genetics , Membrane Glycoproteins/metabolism , Microfilament Proteins/genetics , Oligonucleotide Array Sequence Analysis , Phosphoproteins/genetics , Polymerase Chain Reaction/methods , Proliferating Cell Nuclear Antigen/metabolism , Proteins/genetics , Rats , Rats, Sprague-Dawley , Uterus/drug effects , Uterus/pathology
13.
Mol Hum Reprod ; 8(3): 246-54, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11870232

ABSTRACT

We used a PCR-based subtraction method, representational difference analysis of cDNA (cDNA--RDA), to identify genes with a higher expression in leiomyomas in comparison with the corresponding myometrium during the proliferative phase of the menstrual cycle. Increased expression of the genes for pregnancy-associated plasma protein A (PAPPA), tomoregulin, cellular retinoid acid binding protein 1 (CRABP1), zinc finger protein 185 (ZFP 185) and latent transforming growth factor beta binding protein 2 (LTBP2) was demonstrated in individual leiomyoma samples compared with corresponding myometrium. Additionally, a specific positive immunostaining of LTBP2 was found in the smooth muscle cells of both leiomyomas and myometrium. These genes may be part of previously unidentified molecular mechanisms responsible for the selective growth advantage of leiomyomas compared with myometrium. This work expands our knowledge about the molecular nature of leiomyomas and provides novel candidate genes to further explore in relation to their function during leiomyoma growth.


Subject(s)
Adaptor Proteins, Signal Transducing , Carrier Proteins/genetics , DNA-Binding Proteins/genetics , Endopeptidases/genetics , Gene Expression , Leiomyoma/genetics , Membrane Proteins/genetics , Myometrium/metabolism , Neoplasm Proteins , Pregnancy Proteins/genetics , Pregnancy-Associated Plasma Protein-A , Retinol-Binding Proteins/genetics , Uterine Neoplasms/genetics , Zinc Fingers , Carrier Proteins/metabolism , Cytoskeletal Proteins , Female , Gene Expression Profiling , Humans , Immunohistochemistry/methods , LIM Domain Proteins , Latent TGF-beta Binding Proteins , Retinol-Binding Proteins, Cellular , Retinol-Binding Proteins, Plasma , Transforming Growth Factor beta , Uterus
SELECTION OF CITATIONS
SEARCH DETAIL